Truist Maintains Buy Rating on BeOne Medicines
Truist Securities maintained a Buy rating on BeOne Medicines, per Benzinga ratings actions.
Story updates
03:51:01 PM UTC
SquawkNews
BeOne Medicines Is Maintained at Buy by Truist Securities
03:51:12 PM UTC
SquawkNews
BeOne Medicines Price Target Raised to $420.00/Share From $418.00 by Truist Securities